Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LOXL2 inhibitor (podocyte-specific)
- Development stage
- Preclinical
- Lead developer
- Yonsei University College of Medicine
- Modality
- Small Molecules, Antibody-Based Therapeutics
01
Overview
**LOXL2 inhibitor (podocyte-specific)** refers to a therapeutic strategy or class of investigational agents designed to selectively inhibit Lysyl Oxidase-Like 2 (LOXL2) within renal podocytes. LOXL2 is an enzyme responsible for catalyzing the cross-linking of collagen and elastin in the extracellular matrix, and its aberrant upregulation is strongly associated with tissue fibrosis and remodeling. In the kidney, podocyte-specific LOXL2 expression has been shown to drive sterile inflammation, NLRP3 inflammasome priming, and downstream pro-fibrotic TGF-β/Smad signaling under metabolic and inflammatory stress. Preclinical research, including genetic knockout mouse models (such as *Nphs2-Cre:Loxl2-/-*) and CRISPR/Cas9 gene silencing, has demonstrated that targeting podocyte LOXL2 significantly reduces albuminuria, preserves podocyte structural integrity, and attenuates kidney injury in models of diabetic kidney disease (DKD) and acute kidney injury (AKI) on chronic kidney disease (CKD). Currently, this represents an active area of target validation rather than a single designated clinical-stage drug candidate.
- Other names
- podocyte-specific LOXL2 inhibitor
02
Targets
LOXL2 (Lysyl oxidase-like 2 protein)
Beyond the preview
Go deeper on LOXL2 inhibitor (podocyte-specific).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LOXL2 inhibitor (podocyte-specific).